title: Glycan-based DC-SIGN targeting to enhance antigen cross-presentation in anticancer vaccines.
abstract: In vivo dendritic-cell targeting constitutes a promising strategy for anticancer vaccination. Here, we discuss the usage of multivalent DC-SIGN-targeting glycan platforms that allow for the efficient routing of antigens to the endo-lysosomal pathway as well as to a yet uncharacterized cross-presentation mechanism inducing CD4+and CD8+T-cell responses.
authors.affiliation: Department of Molecular Cell Biology and Immunology; VU University Medical Center; Amsterdam, The Netherlands.
authors.forename: Juan J
authors.initials: JJ
authors.lastname: García-Vallejo
authors.forename: Wendy W J
authors.initials: WW
authors.lastname: Unger
authors.forename: Hakan
authors.initials: H
authors.lastname: Kalay
authors.forename: Yvette
authors.initials: Y
authors.lastname: van Kooyk
keywords: DC-SIGN; cell surface molecules; dendritic cells; glycans; human; rodent